Dementia and movement disorder treatment market to grow at a CAGR of 6.95% from 2021 to 2026: AbbVie Inc. and Biogen Inc. among key vendors - Technavio

NEW YORK, April 13, 2023 /PRNewswire/ -- The dementia and movement disorder treatment market size is forecast to increase by USD 7.14 billion from 2021 to 2026, at a CAGR of 6.95%, according to the recent market study by Technavio. The growth of the market will be driven by the growing geriatric population, the rising prevalence of target diseases, and the emergence of strategies to increase public awareness. Charts & data tables about market and segment sizes for the forecast period (2022-2026) have been covered in this exclusive report. Download the sample PDF report

Vendor analysis: Vendor offerings -

Technavio has extensively analyzed 15 major vendors, including AbbVie Inc., Acorda Therapeutics Inc., Amneal Pharmaceuticals Inc., Bausch Health Companies Inc., Biogen Inc., Eisai Co. Ltd., GlaxoSmithKline Plc, H Lundbeck AS, Johnson and Johnson, Kyowa Kirin Co. Ltd., Lannett Co. Inc., Merck and Co. Inc., Neurocrine Biosciences Inc., Novartis AG, Organon and Co., Orion Pharma Ltd., Otsuka Holdings Co. Ltd., Supernus Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., UCB SA, and Vertical Pharmaceuticals LLC. The key offerings of some of the key vendors are listed below:

• AbbVie Inc. - The company offers treatment for dementia and movement disorder under the brand names Namenda and Duopa.
• Biogen Inc. - The company offers treatment for dementia and movement disorder under the brand name Aduhelm.
• Eisai Co. Ltd. - The company offers treatment for dementia and movement disorder under the brand name Aricept.
• H Lundbeck AS - The company offers treatment for dementia and movement disorder under the brand names Ebixa and Ebix.
• Novartis AG - The company offers treatment for dementia and movement disorder under the brand name EXELON PATCH.

Key benefits for industry players & stakeholders – 

• The report offers information on the criticality of vendor inputs, including R&D, CAPEX, and technology.
• It also provides detailed analyses of the market's competitive landscape and vendors' product offerings.
• The report also provides a qualitative and quantitative analysis of vendors to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

Expand operations in the future - To get requisite details, ask for a custom report now.

Market Segmentation:

The market has been segmented by drug class (MAO inhibitors, acetylcholinesterase inhibitors, glutamate inhibitors, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)).

The MAO inhibitors segment will account for a significant share of the market growth during the forecast period. MAO inhibitors are used as a monotherapy in early Parkinson's disease or as adjunctive therapy in patients with motor-related symptoms of the disease due to their high efficacy and specificity. Thus, the rising prevalence of Parkinson's disease and related disorders is expected to increase the consumption of MAO inhibitors. These factors will drive the dementia and movement disorder treatment market growth during the forecast period.

North America will account for 45% of the market's growth during the forecast period. The US and Canada are the key contributors to the dementia and movement disorder treatment market in the region. Moreover, market growth in North America will be faster than the growth of the market in Rest of World (ROW). Factors such as the growing prevalence of target diseases such as Alzheimer's disease and Parkinson's disease will drive the dementia and movement disorder treatment market growth in the region during the forecast period.

Get a holistic overview of the market from industry experts to evaluate and develop cost-
effective growth strategies. Download the sample PDF report.

Market dynamics:

Key drivers:

• Growing geriatric population
• Rising prevalence of target diseases
• Emergence of strategies to increase public awareness

The geriatric population is increasing globally. For instance, in 2020, 260 million people in Eastern and South-Eastern Asia fell into the age group of 65 years and above. The risk of developing dementia increases with age. According to the World Health Organization (WHO), around 55 million people across the world had dementia as of September 2021. The number of people with dementia is expected to increase to 78 million by 2030 and 139 million by 2050 worldwide. The increase in the geriatric population globally will increase the risk of developing neurological disorders, including dementia. These factors will increase the demand for dementia drugs during the forecast period.

Major trends:

• Emergence of biomarkers
• Growth of gene therapy to reverse cognitive decline associated with Alzheimer's disease
• Advances in biomedical science

Biomarkers provide a better understanding of the pathogenesis of neurodegenerative diseases. Several research strategies identify molecular biomarkers related to Parkinson's disease and dementia. For instance, a research trial involved the analysis of a patient's cerebrospinal fluid and blood samples to target proteins that play a key role in the pathogenesis of Parkinson's disease. Such initiatives are expected to have a positive impact on the market during the forecast period.

Key challenges:

• Rise in the economic burden of neurological disorders
• Failure rates of drugs in clinical trials
• Poor diagnosis of dementia

Alzheimer's disease is one of the leading causes of death in the US, according to the CDC. However, the growing treatment cost is a challenge for patients in the US. According to a study conducted and published by the Michael J. Fox Foundation, along with national organizations in the US, the total cost of Parkinson's disease to individuals, families, and the US government is USD 51.9 billion each year. Thus, the economic burden of the disease is expected to rise, with an increase in the geriatric population in the US. These factors will hamper the dementia and movement disorder treatment market growth.

To get detailed insights about various market challenges along with data inclusions and
exclusions, buy the report

What are the key data covered in this dementia and movement disorder treatment market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the dementia and movement disorder treatment market between 2022 and 2026
• Precise estimation of the size of the dementia and movement disorder treatment market and its contribution to the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the dementia and movement disorder treatment market across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information about vendors
• Comprehensive analysis of factors that will challenge the growth of dementia and movement disorder treatment market vendors

Related Reports:

The neurologic disorders therapeutics market size is expected to grow by USD 33.46 billion from 2021 to 2026 with a progressing CAGR of 5.44%. The market is segmented by application (CNS and PNS) and geography (North America, Europe, Asia, and Rest of World (ROW)). The approval of novel drugs is notably driving the neurologic disorders therapeutics market growth, although factors such as the advent of neurostimulation devices may impede the market growth.

The obsessive-compulsive disorder drugs market size is expected to increase by USD 266.78 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.55%. The market is segmented by product (SSRI, TSA, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)). The rising prevalence of OCD is notably driving the obsessive-compulsive disorder drugs market growth, although factors such as the difficulties in diagnosing OCD may impede the market growth.

Gain instant access to 17,000+ market research reports including key parameters and
data analysis. 
Technavio's SUBSCRIPTION platform

Browse for Technavio Health Care market reports

Table of contents

1 Executive Summary

• 1.1 Market overview 
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Drug Class
• Exhibit 06: Executive Summary – Chart on Incremental Growth
• Exhibit 07: Executive Summary – Data Table on Incremental Growth
• Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem 
• Exhibit 09: Parent market
• Exhibit 10: Market Characteristics

3 Market Sizing

• 3.1 Market definition 
• Exhibit 11: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 12: Market segments

• 3.3 Market size 2021

• 3.4 Market outlook: Forecast for 2021-2026 
• Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
• Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

• 4.1 Five forces summary 
• Exhibit 17: Five forces analysis - Comparison between2021 and 2026

• 4.2 Bargaining power of buyers 
• Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026

• 4.3 Bargaining power of suppliers 
• Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026

• 4.4 Threat of new entrants 
• Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026

• 4.5 Threat of substitutes 
• Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026

• 4.6 Threat of rivalry 
• Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026

• 4.7 Market condition 
• Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Drug Class

• 5.1 Market segments 
• Exhibit 24: Chart on Drug Class - Market share 2021-2026 (%)
• Exhibit 25: Data Table on Drug Class - Market share 2021-2026 (%)

• 5.2 Comparison by Drug Class 
• Exhibit 26: Chart on Comparison by Drug Class
• Exhibit 27: Data Table on Comparison by Drug Class

• 5.3 MAO inhibitors - Market size and forecast 2021-2026
• Exhibit 28: Chart on MAO inhibitors - Market size and forecast 2021-2026 ($ million)
• Exhibit 29: Data Table on MAO inhibitors - Market size and forecast 2021-2026 ($ million)
• Exhibit 30: Chart on MAO inhibitors - Year-over-year growth 2021-2026 (%)
• Exhibit 31: Data Table on MAO inhibitors - Year-over-year growth 2021-2026 (%)

• 5.4 Acetylcholinesterase inhibitors - Market size and forecast 2021-2026 
• Exhibit 32: Chart on Acetylcholinesterase inhibitors - Market size and forecast 2021-2026 ($ million)
• Exhibit 33: Data Table on Acetylcholinesterase inhibitors - Market size and forecast 2021-2026 ($ million)
• Exhibit 34: Chart on Acetylcholinesterase inhibitors - Year-over-year growth 2021-2026 (%)
• Exhibit 35: Data Table on Acetylcholinesterase inhibitors - Year-over-year growth 2021-2026 (%)

• 5.5 Glutamate inhibitors - Market size and forecast 2021-2026
• Exhibit 36: Chart on Glutamate inhibitors - Market size and forecast 2021-2026 ($ million)
• Exhibit 37: Data Table on Glutamate inhibitors - Market size and forecast 2021-2026 ($ million)
• Exhibit 38: Chart on Glutamate inhibitors - Year-over-year growth 2021-2026 (%)
• Exhibit 39: Data Table on Glutamate inhibitors - Year-over-year growth 2021-2026 (%)

• 5.6 Others - Market size and forecast 2021-2026
• Exhibit 40: Chart on Others - Market size and forecast 2021-2026 ($ million)
• Exhibit 41: Data Table on Others - Market size and forecast 2021-2026 ($ million)
• Exhibit 42: Chart on Others - Year-over-year growth 2021-2026 (%)
• Exhibit 43: Data Table on Others - Year-over-year growth 2021-2026 (%)

• 5.7 Market opportunity by Drug Class 
• Exhibit 44: Market opportunity by Drug Class ($ million)

6 Customer Landscape

• 6.1 Customer landscape overview 
• Exhibit 45: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

• 7.1 Geographic segmentation 
• Exhibit 46: Chart on Market share by geography 2021-2026 (%)
• Exhibit 47: Data Table on Market share by geography 2021-2026 (%)

• 7.2 Geographic comparison 
• Exhibit 48: Chart on Geographic comparison
• Exhibit 49: Data Table on Geographic comparison

• 7.3 North America - Market size and forecast 2021-2026
• Exhibit 50: Chart on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 51: Data Table on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 52: Chart on North America - Year-over-year growth 2021-2026 (%)
• Exhibit 53: Data Table on North America - Year-over-year growth 2021-2026 (%)

• 7.4 Europe - Market size and forecast 2021-2026
• Exhibit 54: Chart on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 55: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 56: Chart on Europe - Year-over-year growth 2021-2026 (%)
• Exhibit 57: Data Table on Europe - Year-over-year growth 2021-2026 (%)

• 7.5 Asia - Market size and forecast 2021-2026
• Exhibit 58: Chart on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 59: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 60: Chart on Asia - Year-over-year growth 2021-2026 (%)
• Exhibit 61: Data Table on Asia - Year-over-year growth 2021-2026 (%)

• 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
• Exhibit 62: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 63: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 64: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
• Exhibit 65: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)

• 7.7 US - Market size and forecast 2021-2026
• Exhibit 66: Chart on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 67: Data Table on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 68: Chart on US - Year-over-year growth 2021-2026 (%)
• Exhibit 69: Data Table on US - Year-over-year growth 2021-2026 (%)

• 7.8 Germany - Market size and forecast 2021-2026
• Exhibit 70: Chart on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 71: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
• Exhibit 72: Chart on Germany - Year-over-year growth 2021-2026 (%)
• Exhibit 73: Data Table on Germany - Year-over-year growth 2021-2026 (%)

• 7.9 UK - Market size and forecast 2021-2026
• Exhibit 74: Chart on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 75: Data Table on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 76: Chart on UK - Year-over-year growth 2021-2026 (%)
• Exhibit 77: Data Table on UK - Year-over-year growth 2021-2026 (%)

• 7.10 Canada - Market size and forecast 2021-2026
• Exhibit 78: Chart on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 79: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 80: Chart on Canada - Year-over-year growth 2021-2026 (%)
• Exhibit 81: Data Table on Canada - Year-over-year growth 2021-2026 (%)

• 7.11 France - Market size and forecast 2021-2026
• Exhibit 82: Chart on France - Market size and forecast 2021-2026 ($ million)
• Exhibit 83: Data Table on France - Market size and forecast 2021-2026 ($ million)
• Exhibit 84: Chart on France - Year-over-year growth 2021-2026 (%)
• Exhibit 85: Data Table on France - Year-over-year growth 2021-2026 (%)

• 7.12 Market opportunity by geography 
• Exhibit 86: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges

• 8.3 Impact of drivers and challenges 
• Exhibit 87: Impact of drivers and challenges in 2021 and 2026

• 8.4 Market trends

9 Vendor Landscape

• 9.1 Overview

• 9.2 Vendor landscape 
• Exhibit 88: Overview on Criticality of inputs and Factors of differentiation

• 9.3 Landscape disruption 
• Exhibit 89: Overview on factors of disruption

• 9.4 Industry risks 
• Exhibit 90: Impact of key risks on business

10 Vendor Analysis

• 10.1 Vendors covered 
• Exhibit 91: Vendors covered

• 10.2 Market positioning of vendors 
• Exhibit 92: Matrix on vendor position and classification

• 10.3 AbbVie Inc. 
• Exhibit 93: AbbVie Inc. - Overview
• Exhibit 94: AbbVie Inc. - Product / Service
• Exhibit 95: AbbVie Inc. - Key offerings

• 10.4 Biogen Inc. 
• Exhibit 96: Biogen Inc. - Overview
• Exhibit 97: Biogen Inc. - Product / Service
• Exhibit 98: Biogen Inc. - Key offerings

• 10.5 Eisai Co. Ltd. 
• Exhibit 99: Eisai Co. Ltd. - Overview
• Exhibit 100: Eisai Co. Ltd. - Business segments
• Exhibit 101: Eisai Co. Ltd. - Key offerings
• Exhibit 102: Eisai Co. Ltd. - Segment focus

• 10.6 H Lundbeck AS 
• Exhibit 103: H Lundbeck AS - Overview
• Exhibit 104: H Lundbeck AS - Product / Service
• Exhibit 105: H Lundbeck AS - Key offerings

• 10.7 Johnson and Johnson 
• Exhibit 106: Johnson and Johnson - Overview
• Exhibit 107: Johnson and Johnson - Business segments
• Exhibit 108: Johnson and Johnson - Key news
• Exhibit 109: Johnson and Johnson - Key offerings
• Exhibit 110: Johnson and Johnson - Segment focus

• 10.8 Merck and Co. Inc. 
• Exhibit 111: Merck and Co. Inc. - Overview
• Exhibit 112: Merck and Co. Inc. - Business segments
• Exhibit 113: Merck and Co. Inc. - Key news
• Exhibit 114: Merck and Co. Inc. - Key offerings
• Exhibit 115: Merck and Co. Inc. - Segment focus

• 10.9 Novartis AG 
• Exhibit 116: Novartis AG - Overview
• Exhibit 117: Novartis AG - Business segments
• Exhibit 118: Novartis AG - Key offerings
• Exhibit 119: Novartis AG - Segment focus

• 10.10 Otsuka Holdings Co. Ltd. 
• Exhibit 120: Otsuka Holdings Co. Ltd. - Overview
• Exhibit 121: Otsuka Holdings Co. Ltd. - Business segments
• Exhibit 122: Otsuka Holdings Co. Ltd. - Key offerings
• Exhibit 123: Otsuka Holdings Co. Ltd. - Segment focus

• 10.11 Teva Pharmaceutical Industries Ltd. 
• Exhibit 124: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibit 125: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibit 126: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibit 127: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibit 128: Teva Pharmaceutical Industries Ltd. - Segment focus

• 10.12 UCB SA 
• Exhibit 129: UCB SA - Overview
• Exhibit 130: UCB SA - Product / Service
• Exhibit 131: UCB SA - Key offerings

11 Appendix

• 11.1 Scope of the report

• 11.2 Inclusions and exclusions checklist 
• Exhibit 132: Inclusions checklist
• Exhibit 133: Exclusions checklist

• 11.3 Currency conversion rates for US$ 
• Exhibit 134: Currency conversion rates for US$

• 11.4 Research methodology 
• Exhibit 135: Research methodology
• Exhibit 136: Validation techniques employed for market sizing
• Exhibit 137: Information sources

• 11.5 List of abbreviations 
• Exhibit 138: List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio